产前曲坦类药物暴露与子代神经发育结局的关联
挪威全国健康登记研究纳入26,210例偏头痛孕妇,随访子代至14岁,评估产前曲坦类单用或联合预防性偏头痛药物暴露与神经发育障碍(NDD)的关联。结果显示任何曲坦类轨迹的子代NDD风险较未用药者略高(wHR 1.05-1.16),但以低使用停药者为对照或分析特定结局时风险降至无效,自闭症风险轻度升高但置信区间跨无效且风险差低。结论认为产前曲坦类暴露未实质性增加子代广泛NDD风险。
要点
- 产前曲坦类暴露子代NDD风险较未用药者略高,但幅度小。
- 以低使用停药者为对照时风险降至无效。
- 自闭症风险轻度升高但置信区间跨无效,风险差低。
核心结论
- 产前曲坦类单用或联合其他偏头痛药物暴露未实质性增加子代至青春期广泛神经发育障碍风险。
研究设计与样本
- 挪威全国健康登记研究纳入26,210例孕前偏头痛孕妇,随访子代至14岁。
- 采用基于组的轨迹模型聚类曲坦类暴露,并用倾向评分重叠加权分析。
主要发现
- 子代中1,140例(4.3%)诊断NDD,平均随访8年。
- 任何曲坦类轨迹子代NDD风险较未用药者略高(wHR 1.05-1.16)。
- 以低使用停药者为对照时wHR 0.94-1.01,分析言语/语言障碍或ADHD时wHR 0.82-1.14。
- 两个晚停药轨迹的自闭症风险wHR分别为1.24(95%CI 0.78-1.97)和1.30(95%CI 0.66-2.56),置信区间跨无效。
临床怎么用
- 临床可参考此结果,产前曲坦类暴露未显示实质性增加子代NDD风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The long-term reproductive safety of migraine medications remains uncertain. This study sought to examine the effect of different intensities and durations of prenatal exposure to triptans, alone and combined with other preventive migraine medications, on neurodevelopmental disorders (NDDs) in children. METHODS: This nationwide health registry study in Norway included pregnancies of women with migraine before pregnancy and followed up their children up to 14 years of age. Single and multiple group-based trajectory models and group-based multitrajectory models were applied to cluster triptan exposure alone and combined with preventive antimigraine medications. Child outcomes, based on specialist outpatient and inpatient diagnoses, included autism spectrum and behavioral disorders, learning and intellectual disabilities, speech/language and developmental coordination disorders, and attention-deficit hyperactivity disorders (ADHDs). We fit adjusted and weighted pooled logistic regression models and standardized risk curves using propensity score-based overlap weighting. RESULTS: We included 26,210 pregnancies of women with migraine; 4,929 and 21,281 were, respectively, nonmedicated and medicated with triptans in the year of prepregnancy. In the latter group, we identified 4 group-based trajectories of triptans alone and combined with preventive medications: discontinuers before (low use) (41.5%, 47.0%), early discontinuers (short-term low use) (31.3%, 28.8%), late discontinuers (moderate use) (21.3%, 9.1%), and late discontinuers (high use) (5.9%, 15.2%). Overall, 1,140 children (4.3%) had a NDD (mean follow-up time: 8 years). Children born to women with any triptan trajectory had a slightly higher risk of NDD compared with children of nonmedicated women (magnitude range of the weighted hazard ratio [wHR]: 1.05-1.16). These risks decreased to the null when discontinuers before (low use) acted as a comparator (magnitude of wHR: 0.94-1.01) or when analyzing speech/language disorders or ADHD (magnitude of wHR: 0.82-1.14). There was a slightly elevated risk of autism disorders with both triptan late discontinuation trajectories (wHR 1.24, 95% CI [0.78-1.97]; wHR 1.30, 95% CI [0.66-2.56]), but the 95% CI crossed the null and the weighted risk difference remained low. DISCUSSION: Our findings indicate that prenatal exposure to triptans, alone or combined with other migraine medications, does not substantially increase the risk of a broad range of neurodevelopmental outcomes in children up to adolescence.
引用
- Camanni M, van Gelder MMHJ, Cantarutti A, et al. Association of Prenatal Exposure to Triptans, Alone or Combined With Other Migraine Medications, and Neurodevelopmental Outcomes in Offspring. Neurology. 2025. PMID: 40397854. doi:10.1212/WNL.0000000000213678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。